About this episode

Toon Overbeeke discusses the development and impact of Vitestro's autonomous blood-drawing robot, Aletta, and shares insights on patient adoption and scaling the company.

In this episode of The Crux of MedTech, Henry Norton sits down with Toon Overbeeke, CEO and Co-founder of Vitestro, the company behind the world's first CE-marked autonomous robotic phlebotomy device, Aletta. Fresh off a $70M oversubscribed Series B backed by Labcorp, Mayo Clinic, Sutter Health and Sonder Capital, with Intuitive Surgical founder Fred Moll on the board, Toon shares how a friend's father struggling through chemotherapy blood draws sparked the idea to automate the most commonly performed invasive procedure on the planet. Toon breaks down how Vitestro approached the problem from a business case first, not an engineering push, and why that distinction has kept their thesis intact for nine years. He shares surprising patient adoption data, including the counterintuitive finding that elderly patients are more willing to use the system than younger ones, and the moment a waiting room fight broke out because patients wanted to skip the line to use their robot. He also opens up about the personal evolution required to scale from a two-person team to over 100 FTEs, the trade-offs of managing long-standing team members through company growth, and how having Fred Moll and…

People in this episode

Host: Henry Norton

Guest: Toon Overbeeke

Topics covered

• autonomous robotic blood drawing
• patient adoption data
• business case vs engineering
• scaling a startup
• healthcare innovation

Mentioned in this episode

Organizations: Vitestro, Labcorp, Mayo Clinic, Sutter Health, Sonder Capital

Products: Aletta

More episodes of The Crux of Medtech

• Five Billion-Dollar Deals in 45 Days: Inside the Cardiac Monitoring Gold Rush with Ken Nelson · June 5, 2026 · 52 min

Explore listener stats, chart rankings, contacts and more on the The Crux of Medtech podcast page.